Regeneron Pharmaceuticals Inc. announced positive results from a Phase 1/2 trial for Lynozyfic in adults with newly diagnosed multiple myeloma. The data showed impressive efficacy with 70% of patients achieving very good partial response or better. Additionally, 95% of evaluable patients achieved minimal residual disease negative status. These findings were presented at the ASH Annual Meeting, highlighting Lynozyfic’s potential to deliver meaningful outcomes for patients with multiple myeloma. The results are part of Regeneron’s broader clinical development program for Lynozyfic in early lines of treatment.

Read more at Nasdaq: Regeneron Reports Promising Phase 1/2 Data Of Lynozyfic In Newly Diagnosed Multiple Myeloma